Roger Dansey, M.D., Chief Medical Officer, brings extensive experience in cancer drug development to Seattle Genetics and is responsible for growing, approved drug ADCETRIS® (brentuximab vedotin) and advancing a novel late-stage oncology pipeline. Seattle Genetics is the largest biotech based in the Pacific Northwest and an emerging multi-product, global biotechnology company. Prior to joining Seattle Genetics in May 2018, Dr. Dansey served as Therapeutic Area Head for Late Stage Oncology at Merck Inc. where he was responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. Prior to Merck, Dr. Dansey was Vice President, Oncology Clinical Research at Gilead Sciences. Earlier in his career, he held various roles of increasing responsibility in Amgen’s oncology and hematology therapeutic areas, including as Global Development Leader for XGEVA®. Dr. Dansey received his Medical Degrees from the University of Witwatersrand, Johannesburg, South Africa.